The American Heart Association has announced a Data Grant focused on cardiovascular, kidney and metabolic (CKM) syndrome in people with current or prior cancer. The initiative aims to quantify and address CKM disease among cancer patients and survivors by analyzing real‑world data to understand prevalence, treatment patterns, shared risk factors and outcomes.
Projects should leverage large datasets such as electronic health records, registries or claims databases to produce actionable insights in cardio‑oncology. Analyses that clarify management patterns, identify high‑risk populations or evaluate outcomes across cancer survivorship are priorities.
Eligibility is open to independent investigators at academic, clinical or public‑health institutions worldwide. Proposals must center on cancer patients or survivors and CKM disease, and applicants must demonstrate access to, and the ability to securely analyze, appropriate real‑world datasets.
Multidisciplinary teams are encouraged, including expertise in oncology, cardiology, nephrology, epidemiology and data science. Collaborative proposals that integrate clinical and population‑level data are preferred.
Funding is provided through an AHA targeted research grant mechanism using large real‑world datasets. Budgets and project duration must follow AHA policies for this request for proposals, with indirect costs capped according to current AHA rules. Applicants should propose a justified budget within program limits.
Key dates: Letter of Intent deadline is January 19, 2026. Full applications are by invitation only, with a deadline of March 23, 2026. The earliest project start date is August 1, 2026.
See program details for more information.
Leave a Reply